Andrea L. Webber

TL;DR: Pembrolizumab was effective and tolerable in patients with advanced hepatocellular carcinoma who had previously been treated with sorafenib and is undergoing further assessment in two phase 3, randomised trials as a second-line treatment.

TL;DR: The potential for TMB and a T cell–inflamed GEP to jointly predict clinical response to pembrolizumab was assessed in >300 patient samples with advanced solid tumors and melanoma across 22 tumor types from four KEYNOTE clinical trials.

TL;DR: A high fat/sugar water-induced animal model of NAFLD that closely mimics most aspects of human disease is validated and involves a metabolic perturbation which triggers subsequent cell stress and inflammation driving cell death and turnover.

TL;DR: Detailed characterization of this animal model provides the first in vivo evidence that Elovl4 haploinsufficiency is not the underlying key disease mechanism in STGD3, and results are consistent with a dominant negative mechanism for the deletion mutation.

TL;DR: The identification of two sets of Nr2e3-regulated genes provides further evidence of a dual role for Nr 2e3 in specification of photoreceptor fate during development as well asPhotoreceptor maintenance in the adult.